Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 study

Thomsen Frederik B.; Brasso Klaus; Christensen Ib J.; Johansson Jan-Erik; Angelsen Anders; Tammela Teuvo L. J.; Iversen Peter

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 study

【24h】

Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 study

机译：早期雄激素受体抑制剂治疗在局部晚期前列腺癌中的生存获益：SPCG-6研究的长期随访

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: The optimal timing of endocrine therapy in non-metastatic prostate cancer (PCa) is still an issue of debate.

机译：背景：非转移性前列腺癌（PCa）中内分泌治疗的最佳时机仍是一个有争议的问题。

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2015年第10期|共10页
作者
Thomsen Frederik B.; Brasso Klaus; Christensen Ib J.; Johansson Jan-Erik; Angelsen Anders; Tammela Teuvo L. J.; Iversen Peter;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
Antiandrogen; Bicalutamide; Localised; Locally advanced; Prostate cancer; Survival;

机译：抗雄激素;比卡鲁胺;局部;局部晚期;前列腺癌;生存;

相似文献

外文文献
中文文献
专利

1. Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 study [J] . Thomsen Frederik B., Brasso Klaus, Christensen Ib J., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2015,第10期

机译：早期雄激素受体抑制剂治疗在局部晚期前列腺癌中的生存获益：SPCG-6研究的长期随访
2. Sex or survival: short-term versus long-term androgen deprivation in patients with locally advanced prostate cancer treated with radiotherapy. [J] . Wilke DR, Krahn M, Tomlinson G, Cancer: A Journal of the American Cancer Society . 2010,第8期

机译：性别或生存：局部晚期雄激素剥夺与局部晚期前列腺癌患者放疗比较。
3. Second Cancers in Patients With Locally Advanced Prostate Cancer Randomized to Lifelong Endocrine Treatment With or Without Radical Radiation Therapy: Long-Term Follow-up of the Scandinavian Prostate Cancer Group-7 Trial [J] . Aksnessaether Bjorg Y., Myklebust Tor Age, Solberg Arne, International Journal of Radiation Oncology, Biology, Physics . 2020,第4期

机译：患有局部晚期前列腺癌的患者的第二种癌症随机终身治疗或没有激进的放射治疗：斯堪的纳维亚前列腺癌组的长期随访 - 7试验
4. Role of the Androgen Receptor and PI3K/Akt in the Survival of Androgen-Refractory Prostate Cancer Cells [C] . Haojie Huang, Donald J. Tindal International Symposium on Hormonal Carcinogenesis . 2005

机译：雄激素受体和PI3K / AKT在雄激素难治性前列腺癌细胞存活中的作用
5. Therapeutic Targeting of Stat5a/b in Advanced Prostate Cancer: Inhibition of Stat5a/b Suppresses Growth of Prostate Cancer through Mechanisms Dependent and Independent of Androgen Receptor. [D] . Hoang, David Timothy. 2016

机译：Stat5a / b在晚期前列腺癌中的治疗靶点：Stat5a / b的抑制作用通过依赖于雄激素受体的机制来抑制前列腺癌的生长。
6. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer [O] . Mark Thalgott, Thomas Horn, Matthias M Heck, 2014

机译：新辅助多西他赛化疗及完全雄激素阻断治疗局部晚期和高危前列腺癌的II期研究的长期结果
7. Long-Term Androgen Deprivation, With or Without Radiation Therapy, in Locally Advanced Prostate Cancer: Results From a Phase 3 Randomized Study After 7.3 Years' Median Follow-up [O] . P. Sargos, N. Mottet, V. Molinie, 2016

机译：长期雄激素剥夺，有或没有放射治疗，在局部晚期前列腺癌中：7.3岁的中位后续后的第3期随机研究的结果
8. Multivalent Peptidomimetic Conjugates as Inhibitors of Androgen Receptor Function in Therapy-Resistant Prostate Cancer. [R] . Kirshenbaum, K. 2017

机译：多价拟肽结合物作为抗癌前列腺癌中雄激素受体功能的抑制剂。

Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 study

摘要

著录项

相似文献

相关主题

期刊订阅